With atrial fibrillation (AF) being the most common type of heart complication that affects the patient’s heart rhythms, various studies have looked into the best treatment options as well as numerous other factors that may aid in early detection. One such study, which was presented at the American College of Cardiology’s 62nd Annual Scientific Session, found that AF affects men and women differently, in that men are more likely to die from the condition.
For this study, researchers monitored information collected from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF). The ORBIT AF registry included information on over 10,000 male and female patients who are suffering from AF. During their research, they found that men were more likely to suffer from strokes, heart palpitations, shortness of breath, dizziness, fatigue and chest discomfort compared to the women. This fact was regardless of whether they suffered from the same type of AF.
What makes this research significant is that in knowing that AF affects men and women differently, treatments can be found that work better for the patient. So far, patients are often treated with anticoagulant medications and ablations. However some anticoagulants, like Multaq, have been proven to be far more dangerous than the condition. Made by Sanofi-Aventis, Multaq has been linked to serious side effects including a worsening of the heart condition, liver failure and lung toxicity. It is for this reason that the FDA has recommended that doctors only prescribe Multaq if all other medications fail to work.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.